# Donald Trump Type: Person Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/donald-trump Canonical HTML page: https://getbiobrief.com/entity/donald-trump ## Timeline - **2026-02-21**: Market Assessment — Analysts begin evaluating the long-term impact on Novartis's margins and the broader pharma supply chain. - **2026-02-20**: Expansion Announcement — President Trump publicly states that Novartis will expand its U.S. manufacturing footprint due to tariffs. - **2026-02-20**: Ministerial Warning — Health Minister José Ángel Portal Miranda warns of a looming humanitarian crisis in an AP interview. - **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute. - **2026-02-18**: White House Meeting — CEO Vas Narasimhan meets with President Trump to discuss the pharmaceutical industry and trade. - **2026-02-15**: Logistical Collapse — Ambulance services and medical supply flights begin widespread suspensions due to lack of fuel. - **2026-02-10**: Political Controversy — Reports emerge that the vaccine chief overruled career scientists to block the shot. - **2026-01-25**: U.S. Executive Order — President Trump signs order imposing tariffs on any nation providing oil to the Cuban government. - **2026-01-10**: Refusal to File — FDA issues a shocking rejection of the application, sparking a public dispute. - **2026-01**: Venezuelan Oil Cutoff — U.S. announces end of Venezuelan oil shipments to Cuba following political shifts in Caracas. - **2025-11-15**: Initial BLA Submission — Moderna submits its Biologics License Application for mRNA-1010. ## Recent coverage (9 stories) ### Medicare Part D Subsidy Ends: How Pharma & Biotech Face a $3.6B Shift in Patient Costs 2026-07-30 21:24:46 · Sentiment: Bearish · Impact: 7/10 · Sources: 5 Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations. Full story: https://getbiobrief.com/story/medicare-part-d-subsidy-pharma-biotech-impact ### $200B 'Gentleman Scientist' Plan May Unleash a Biotech R&D Renaissance 2026-07-23 23:35:06 · Sentiment: Bullish · Impact: 8/10 · Sources: 2 The White House’s proposal to replace institutional grants with $200B in portable fellowships and golden tickets could dramatically reshape biotech R&D. Startups might gain direct access to top-flight researchers, while big pharma could see its steady university pipeline disrupted. For the biopharma sector, the plan is a high-stakes bet on curiosity-driven discovery over managed research. Full story: https://getbiobrief.com/story/trump-science-overhaul-biotech ### 49-Year Species Rule Ends: Biotech’s Natural Drug Library Faces Extinction Risk 2026-07-18 04:08:25 · Sentiment: Neutral · Impact: 8/10 · Sources: 9 The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms. Full story: https://getbiobrief.com/story/us-ends-blanket-protections-bio-drug-pipeline ### Trump Administration Probes State Mandates for Abortion Coverage 2026-03-19 21:19:21 · Sentiment: Neutral · Impact: 6/10 · Sources: 2 The Trump administration has launched a federal investigation into states that mandate abortion coverage in private health insurance plans. This move leverages federal conscience protection laws to challenge state-level healthcare regulations, potentially jeopardizing billions in federal funding. Full story: https://getbiobrief.com/story/trump-investigation-state-abortion-coverage-mandates ### Geopolitical Conflict in Middle East Threatens Global Pharma Supply Chains 2026-03-07 04:07:56 · Sentiment: Bearish · Impact: 9/10 · Sources: 2 The escalating conflict between the U.S., Israel, and Iran has paralyzed the Strait of Hormuz, causing a surge in energy prices and disrupting critical trade routes. For the pharmaceutical industry, this geopolitical instability threatens the global supply of raw materials and increases the cost of temperature-controlled logistics. Full story: https://getbiobrief.com/story/middle-east-conflict-pharma-supply-chain-impact ### Biotech’s Two-Speed Market: Innovation Defies Regulatory Headwinds 2026-02-25 00:12:53 · Sentiment: Neutral · Impact: 6/10 · Sources: 5 The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises. Full story: https://getbiobrief.com/story/biotech-two-speed-market-analysis-2026 ### US Fuel Blockade Pushes Cuba’s Healthcare System to the Brink of Collapse 2026-02-21 00:34:40 · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2 A severe energy crisis triggered by intensified U.S. sanctions and a fuel blockade has brought Cuba's healthcare infrastructure to a near-total standstill. With hospitals facing persistent power outages and ambulances grounded by fuel shortages, the island is facing an unprecedented humanitarian emergency. Full story: https://getbiobrief.com/story/cuba-healthcare-crisis-us-fuel-blockade ### Trump Credits Tariffs for Novartis Manufacturing Expansion in US 2026-02-20 11:59:37 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 President Donald Trump announced that Novartis AG will expand its U.S. manufacturing footprint following a White House meeting with CEO Vas Narasimhan. The administration attributes this shift to the impact of trade tariffs, signaling a potential trend of onshoring for major pharmaceutical players. Full story: https://getbiobrief.com/story/trump-tariffs-novartis-us-expansion ### FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute 2026-02-18 18:51:48 · Sentiment: Bullish · Impact: 8/10 · Sources: 6 Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application. Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-shot-review --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.